Netherlands· NL-c5e9ca3ac042
Olmesartan medoxomil VELKA 40 mg filmomhulde tabletten
A olmesartan medoxomil product containing olmesartanmedoxomil, registered in Netherlands by Velka Hellas S.A.. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Olmesartan medoxomil is registered in 15 of 19 countries.
Countries holding a registration under ATC C09CA08 (olmesartan medoxomil), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Olmesartan medoxomil · ATC C09CA08
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of olmesartan medoxomil costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.33 in Italy to $0.86 in Switzerland — a ×2.6 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Olmesartan medoxomil · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.86
- ES Spain$0.41
- IT Italy$0.33
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- OLMESARTANMEDOXOMIL
- Manufacturer
- Velka Hellas S.A.
- Country
- Netherlands (NL)
- ATC code
- C09CA08
- ATC class
- Olmesartan medoxomil
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id133066
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
216 interactions on record for olmesartan medoxomil.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Olmesartan medoxomil · interactions on record
216 records
- 7 severe
- 128 moderate
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium gluconateA12BA05severe
- Potassium chlorideB05XA01severe
81 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Olmesartan medoxomil in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f0df53d8-0473-413c-92b2-bfa81e9495a8 GET /v1/drugs/f0df53d8-0473-413c-92b2-bfa81e9495a8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h133066_smpc_en.pdf",
"strength": null,
"atc_label": "Olmesartan Medoxomil",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133066",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"OLMESARTANMEDOXOMIL"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133066_piluk.pdf",
"authorised_at": "2025/09/02",
"procedure_number": "NL/H/6086/003",
"dispensing_status": "Uitsluitend recept",
"registration_number": "133066",
"additional_monitoring": "N"
}See everything about olmesartan medoxomil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.